The HDAC6‐selective inhibitor is effective against non‐Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma

Volume: 58, Issue: 6, Pages: 944 - 956
Published: Feb 27, 2019
Abstract
Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma (NHL) with genetic alterations of BCL-2, KMT2B, and KMT6. FL is refractory to conventional chemotherapy and is still incurable in most patients. Thus, new drugs and/or novel combination treatment strategies are needed to further improve FL patient outcome. We investigated the efficacy of the histone deacetylase 6 (HDAC6) inhibitor A452 combined with a Bruton's...
Paper Details
Title
The HDAC6‐selective inhibitor is effective against non‐Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma
Published Date
Feb 27, 2019
Volume
58
Issue
6
Pages
944 - 956
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.